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Abstract
Background—Type 1 diabetes (T1D) is a clinically heterogeneous disease. The presence of
associated autoimmune diseases (AAID) may represent a distinct form of autoimmune diabetes,
with involvement of specific mechanisms. The aim of this study was to find predictors of AAID in
the Type 1 Diabetes Genetics Consortium (T1DGC) data set.
Methods—3263 families with at least 2 siblings with T1D were included. Clinical information
was obtained using questionnaires, anti-GAD and anti-IA-2 were measured and HLA-genotyping
was performed. Siblings with T1D with and without AAID were compared and a multivariate
regression analysis was performed to find predictors of AAID. T1D-associated HLA haplotypes
were defined as the 4 most susceptible and protective, respectively.
Results—AAID was present in 14.4% of the T1D affected siblings. Age of diabetes onset,
current age and time since diagnosis were higher, and there was a female predominance and more
family history of AAID in the group with AAID, as well as more frequent anti-GAD and less
frequent anti-IA2 positivity. Risk and protective HLA haplotype distributions were similar, though
DRB1*0301-DQA1*0501-DQB1*0201 was more frequent in the group with AAID. In the
multivariate analysis, female gender, age of onset, family history of AAID, time since diagnosis
and anti-GAD positivity were significantly associated with AAID.
Conclusions—In patients with T1D, the presence of AAID is associated with female
predominance, more frequent family history of AAID, later onset of T1D and more anti-GAD
antibodies, despite longer duration of the disease. The predominance of certain HLA haplotypes
suggests that specific mechanisms of disease may be involved.
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Introduction
Type 1A diabetes is a clinically heterogeneous autoimmune disease. Its course ranges from
early, aggressive destruction of beta-cells to slow progression, where patients need insulin
months to years after diagnosis. Although patients are typically young and lean, these
features do not account for all, or even most affected subjects [1]. T1D is associated with an
increased risk of associated autoimmune diseases (AAID), not only in the patients, but also
in their relatives [2, 3]. Different AAID also cluster in individuals [4] and families; indeed,
the risk of suffering an AAID is higher in 1st degree relatives of probands with T1D who
already have an additional autoimmune disease [2]. Hence, the presence of AAID may
represent a distinct form of autoimmune diabetes, with involvement of specific mechanisms.
The Type 1 Diabetes Genetics Consortium (T1DGC) is an international effort aimed at the
study of the genetics and pathogenesis of T1D[5-7]. With thousands of families with T1D
included from all over the world, this collection represents an extraordinary resource, not
only of samples and genetic data, but also of associated clinical information. However, most
of the reports published so far focus on the genetic results of the Consortium. In this study,
we aim to identify both genetic and clinical predictors of the presence of AAID in subjects
with type 1 diabetes. For this purpose, we selected two siblings per family, affected with
type 1 diabetes, and compared those who did and those who did not have AAID. We
performed multivariate analyses to identify factors associated with AAID in these subjects.
Methods
A total of 3304 families (441 trios) were included in the dataset analysed (available on 1st
July 2009). Inclusion criteria have been described previously [5]. Briefly, an eligible family
consisted of at least 2 siblings with T1D diagnosed before the age of 35 and treated with
insulin within 6 months of diagnosis without an interruption longer than 6 months thereafter.
Occasional exceptions were made to these criteria (through assessment by an eligibility
committee) if other clinical data supported the diagnosis of type 1 diabetes. The parents of
the affected sibpair, all affected and up to 2 unaffected siblings were invited to participate if
available. In population groups with a low prevalence of type 1 diabetes, trio families,
consisting of one affected patient and his/her parents, were also included. In order to avoid
duplication, each family member was asked if they had participated in this study before a
new inclusion was started. All of the participating centers were approved by the Office for
Human Research Protection (Department of Health and Human Services, US). The local
Ethics Committees approved the study and all participants signed a written informed consent
before inclusion.
Clinical information was obtained using questionnaires delivered at each of the participating
centers. Information was obtained directly from the participating family members and/or
from their clinical records. Clinical data obtained included gender, ethnic background, age
of onset, family history of diabetes, estimated body size at diagnosis (categorised as heavy,
normal, thin) and self-reported AAID. AAID was considered to be present if any of the
following was reported: thyroid, celiac or Addison’s disease, rheumatoid arthritis, multiple
sclerosis, systemic lupus erythematosus, vitiligo, psoriasis, inflammatory bowel disease,
pernicious anemia or myasthenia gravis.
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Glutamic acid decarboxylase (GAD65 [GADA]) and the intracellular portion of protein
tyrosine phosphatase (IA-2ic [IA-2A]) antibodies were measured in three central laboratories
(Bingley et al, Bristol, UK (for the European and UK networks); Colman et al, Southbank,
AUS (for the Asia-Pacific Network) and Eisenbarth et al, Aurora, CO, US (for the North
American Network)) in serum from all the affected siblings. All laboratories used similar
radio-binding assays, with different local standards, with values assigned by calibration
against the World Health Organization (WHO) reference reagent. Results reported on
samples included in the Diabetes Autoantibody Standardization Program (DASP) were
compared, and standard methods for reporting in WHO units/mL were developed [8]. When
antibody titres were above values in the standard curve, index estimations were chosen,
since they gave a higher concordance among labs than extrapolation [8]. High antibody
titres were defined as values above the respective standard curve.
HLA-genotyping was also performed centrally (Noble, Erlich et al, Oakland, CA, US, for
the North American Network; Tait et al, Melbourne, Australia, for the Asia-Pacific Network
and Carlson et al, Malmö, Sweden, for the European and UK Networks) in all participating
family members, using a PCR-based, sequence-specific oligonucleotide probe system, as
previously described [9]. Images of the results were scanned, and probe intensities were
measured as pixel values and then imported into Sequence Compilation and Rearrangement
Evaluation (SCORE) software for final genotype calling. T1D-related high-risk and
protective haplotypes were defined according to previous data from the T1DGC [9], i.e.
DRB1*0405-DQA1*0301-DQB1*0302 (DR4), DRB1*0401-DQA1*0301-DQB1*0302
(DR4), DRB1*0301-DQA1*0501-DQB1*0201 (DR3) and DRB1*0402-DQA1*0301-
DQB1*0302 (DR4) as those associated with highest susceptibility and DRB1*0701-
DQA1*0201-DQB1*0303 (DR7), DRB1*1401-DQA1*0101-DQB1*0503 (DR6),
DRB1*1501-DQA1*0102-DQB1*0602 (DR2) and DRB1*1104-DQA1*0501-DQB1*0301
(DR11), as those associated with strongest protection.
Statistical analysis was performed using SPSS for Windows (SPSS Inc, Chicago, IL, US)
and R. Continuous variables are described as median (range) and qualitative variables, as
percentages. Differences between siblings with and without AAID were analysed using
Wilcoxon-Mann-Whitney’s test and chi-squared. Yates’ correction was applied to the latter,
except in 2×2 tables where the expected frequency for a cell was below 5, in which case
Fisher’s exact test was used. Differences in the distribution of high-risk, protective and
single HLA-DRB1-DQA1-DQB1 haplotypes were also analysed (Chi-squared with Yates’
correction, or Fisher’s exact test, as described above) in the subjects with unequivocal
haplotypes.
To identify factors associated with AAID, a multivariate regression analysis (general
additive model) was performed. In order to avoid interference by family size (i.e, bias in
favour of factors present in larger families), only 2 affected siblings per family (the first 2
diagnosed, present in most families) were included in the analysis. Gender, age of onset,
time since diagnosis, antibody positivity and presence of AAID in first degree participating
relatives were included in the model as independent variables and analysed in all the
families. In addition, the number of HLA haplotypes, associated with high risk of, or
protection from T1D, were added to the model. Furthermore, the specific HLA haplotypes
associated with higher risk of AAID in the descriptive analysis were included in a model
together with the clinical predictors. For the latter analyses, we only included the families in
whom DRB1-DQA1-DQB1 haplotypes could be unequivocally inferred. In order to identify
factors specifically associated with single disorders, the multivariate analysis was repeated
using the most common AAID, i.e. thyroid and celiac disease, as dependent variables.
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Information about AAID status was available from 12973 of the 14620 participants.
Unequivocal HLA haplotypes could be inferred in 11016 participants (5152 with type 1
diabetes), from 2711 families.
A total of 12.5% of the participants without and 14.7% of the participants with T1D had at
least 1 AAID (p=0.0002). When relatives with and without T1D were compared, T1D
tripled the risk [OR: 3.07 (2.00-4.72)] of AAID (Mantel-Haenszel chi-square, p= 2.03*10-7),
after adjusting for the presence of first-degree relatives with AAID.
Of the 1279 non-diabetic siblings analysed, 7.6% had AAID (see table 1). The latter were
female (68.9% vs 50.5%, p=0.001) and had a first degree relative with AAID (60,3% vs
32.8%, p<0.00001).more frequently
Information on AAID was available from 6262 of the 6270 siblings with T1D: 9.2% had
thyroid disease, 2.7% celiac disease, 1.2% psoriasis, 1.1% vitiligo, 0.9% rheumatoid
arthritis, 0.4% inflammatory bowel disease and 0.5% other disorders). Most (N=807; 12.9%)
had only one AAID, 82 (1.3%) had 2, 8 (0.1%) had 3 and 2 (0.03%) had 4.
Differences between diabetic siblings with and without AAID
Age of onset of T1D, current age and time since diagnosis, were higher and there was a clear
female predominance in the diabetic siblings with AAID (see table 1). GADA positivity was
more frequent, whereas IA-2A positivity was less frequent in subjects with AAID and
similar results were observed when antibody titres were considered instead of positivity/
negativity (see table 1). Number of (diabetes-related) risk and protective DRB1-DQA1-
DQB1 haplotypes were similar in both groups: of the patients with AAID, 43.5% had one
high-risk haplotype and 37.2% had two, as compared to 39.1% and 38.9%, respectively, in
the group without AAID (p= 0.10). None of the T1D siblings had 2 protective haplotypes
and 1.8% of the siblings with and 1.4% of the patients without AAID had one (p= 0.57).
When single HLA haplotypes were analysed separately, DRB1*0301-DQA1*0501-
DQB1*0201 (DR3), DRB1*0401-DQA1*0301-DQB1*0301 and DRB1*0404-DQA1*0301-
DQB1*0302 (DR4) showed most significant susceptibility, whereas DRB1*1502-
DQA1*0102-DQB1*0502 and DRB1*1502-DQA1*0101-DQB1*0501 were associated with
highest protection against AAID (see table 3).
Factors associated with AAID
In the multiple regression analysis, female gender, age of onset, time since diagnosis, having
a 1st degree relative with AAID and GADA positivity were significantly associated with
AAID (see table 2). Similar results were obtained in the models using GADA and IA-2A
titres instead of positivity (data not shown). In addition, similar results were obtained when
all the affected siblings (and not only 2 per family) were included in the regression analysis
and when only the first diagnosed or the second diagnosed siblings were analysed separately
(data not shown). When the number of type 1 diabetes -associated, high-risk and protective
HLA haplotypes were included in the model, none of them showed to be a significant
predictor of AAID (data not shown). However, when the AAID-related risk haplotypes were
included in the model, they, too, predicted the presence of AAID (p= 0.0018, OR 1.25
(1.08-1.43) per haplotype), whereas the protective haplotypes did not, and GADA positivity
lost its significance. Similar results were obtained when the most frequent AAID (thyroid
and celiac disease) were analysed separately (instead of AAID globally) as dependent
variables. For thyroid disease, the following were significantly associated with the disease:
female gender (p = 2*10-16), having a 1st degree relative with AAID (p = 2*10-16), time
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since diagnosis of type 1 diabetes (p = 2*10-16), older age of onset (4.45*10-6), GADA
positivity (p<0.005) and number of AAID-associated risk HLA haplotypes (p<0.0005) and,
for celiac disease, female gender (p = 2.26*10-10), having a 1st degree relative with AAID
(p = 2.61*10-10), time since diagnosis of type 1 diabetes (p = 1.96*10-7), younger age of
onset (p = 2*10-16), IA-2A negativity (p<0.001) and number of AAID-associated risk HLA
haplotypes (p=4.37*10-13).
Discussion
In the present study, we identified a distinct group of type 1 diabetes patients with AAID,
who were predominantly female, had developed type 1 diabetes later and were more
frequently GADA positive and had higher GADA titres, despite longer duration of the
disease, than diabetic patients without AAID. The predominance of certain HLA haplotypes
in this group suggests that specific mechanisms of disease might be involved.
The use of the T1DGC dataset to explore our hypothesis has two main advantages: the size
of the sample and the homogeneity and high quality of data collection [10], including
clinical information, but also GADA and IA-2A measurements, as well as a vast genetic
database. Furthermore, the inclusion of parents in the study allows HLA haplotypes to be
inferred to an extent, which is not possible in case-control studies. To date, most of the
publications from the T1DGC have focused on the genetic risk of type 1 diabetes, but have
not assessed the determinants of clinical presentation of the disease. In this report, we
present a different approach to the analysis of the T1DGC data, focusing on the prediction of
AAID in patients with type 1 diabetes. We are aware, however, that the study has some
limitations: AAID were self-referred in most cases and no organ-specific auto-antibodies
were measured (except for GADA and IA-2A). The prevalence of different AAID in this
study is similar to that reported in other studies assessing clinically significant disease, but
lower than in those measuring organ-specific antibodies [2, 11, 12]. An underestimation of
the prevalence of AAID may have diluted the potential differences between the study
groups. Therefore, the significant markers of AAID described in this study are probably true
positive findings, although small but clinically significant predictors may have been lost to
identification. Furthermore, the results may be applicable to the most prevalent AAID (i.e
celiac and thyroid disease), but not necessarily to other diseases which are less frequent in
this population. In addition, the analysis was cross-sectional, performed in a very specific
population of families including at least two siblings with type 1 diabetes, diagnosed before
the age of 35 in most cases. Familial type 1 diabetes represents a minority of the patients
suffering from the disease. Results are not necessarily expected to represent sporadic type 1
diabetes, or disease diagnosed later in life, where they would have to be confirmed. On the
other hand, although most of the participants analysed are Caucasian [9], families have been
included in many parts of the world, a fact, which would highlight factors common to very
different environments.
Both female gender and age have previously been associated with autoimmune disease
[12-15]. In addition, GADA, but not IA-2A, have been associated with other AAID, even in
the absence of T1D [4, 16-18] and have been proposed as markers of more unspecific
autoimmunity [19, 20]. GADA positivity and high GADA titres are associated with thyroid
autoimmunity both in classical type 1 diabetes [4, 15] and in patients with LADA [21].
Unlike IA-2, GAD65 is found not only in pancreatic islets, but also in brain and, with lower
expression, in thyroid and pituitary glands, kidney, liver, adrenal glands and gonads [22, 23].
GADA positivity is more frequent in carriers of DR3 (DRB1*0301) and/or DQB1*0201
(DQ2) alleles, whereas IA-2A positivity has been positively correlated with DQ8
(DQB1*0302) and/or DR4 (DRB1*0401, 0402, 0405) and negatively, with DR3
(DRB1*0301)/DQB1*0201 (DQ2) [20, 24, 25]. The DR4-DQ8 haplotype confers the highest
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risk for type 1 diabetes [9] whereas DR3 confers a more broad-based risk for a spectrum of
autoimmune diseases [26, 27]. In this setting, the results of the present study suggest that
HLA genotypes may have an influence on the expression of IA-2A and GADA. Indeed,
when AAID-associated HLA haplotypes were included in the multivariate analysis model,
GADA positivity was no longer significantly associated with AAID, probably because HLA
explained that association.
Some of the HLA haplotypes associated with AAID in the present study are also known to
be associated with type 1 diabetes in the same direction (DRB1*0301-DQA1*0501-
DQB1*0201, DRB1*0404-DQA1*0301-DQB1*0302, DRB1*1502-DQA1*0101-
DQB1*0501, DRB1*0403-DQA1*0301-DQB1*0302, DRB1*0101-DQA1*0101-
DQB1*0501), whereas others are inversely associated (DRB1*0401-DQA1*0301-
DQB1*0301, DRB1*0401-DQA1*0301-DQB1*0302) or neutral (DRB1*0404-DQA1*0301-
DQB1*0402, DRB1*1502-DQA1*0102-DQB1*0502) on type 1 diabetes risk [9]. When the
most prevalent AAID, i.e. thyroid and celiac disease, were analysed separately as dependent
variables, similar, though not identical, predictors were found. Indeed, age of onset of type 1
diabetes showed an inverse relationship (older for thyroid disease, younger for celiac
disease). This suggests common mechanisms for multiple AAID, combined with disease-
specific factors [28]. Some of these mechanisms are also common to type 1 diabetes, as
shown by the increased risk of AAID conferred by the former in family members. However,
the fact that multivariate analysis was performed in siblings with the disease should account
for the effect of diabetes itself and allow us to identify factors, unrelated to diabetes, which
increase the risk of other AAID.
Conclusions
In summary, the present investigation identifies a subgroup of patients with type 1 diabetes
who have AAID, female predominance, later onset of the disease, high GADA positivity
and an increased frequency of certain HLA haplotypes, including DRB1*0301-DQA1*0501-
DQB1*0201. This may represent a specific form of the disease, maybe less aggressive on
the beta-cell, but also less organ-specific, mediated by GADA.
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Table 2
Multiple regression analysis: predictors of AAID in siblings with type 1 diabetes
Variable P OR (95% CI)
Female gender 2×10-16 2.36 (1.98-2.82)
Age of Onset (per year) 0.0014 Non-linear
Time since diagnosis (per year) 2.9 ×10-15 Non-linear
GADA positivity 0.038 1.22 (1.02-1.46)
Family history of AAID (per participating relative) 2×10-16 2.56 (2.13-3.08)
IA-2A positivity 0.075 0.85 (0.71-1.02)
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Table 3
HLA haplotypes most significantly associated with risk of/ protection from associated autoimmune disease
(AAID) in siblings with type 1 diabetes
HLA haplotype DRB1-DQA1-DQB1 Frequency of haplotype in
siblings with AAID (%)
Frequency of haplotype in
siblings without AAID (%)
OR (95% CI) p
0301-0501-0201 51.80 47.53 1.19 (1.06-1.33) 0.0025
0401-0301-0301 6.39 4.73 1.37 (1.08-1.73) 0.0080
0404-0301-0302 11.49 9.54 1.23 (1.03-1.47) 0.021
0404-0301-0402 0.34 0.08 4.06 (1.04-14.11) 0.022
1502-0102-0502 0.13 0.77 0.18 (0.02-0.66) 0.0032
1502-0101-0501 0 0.40 0 (0-0.66) 0.0072
0403-0301-0302 0.61 1.27 0.48 (0.21-0.94) 0.027
0101-0101-0501 10.33 12.54 0.80 (0.67-0.96) 0.017
0401-0301-0302 31.95 34.57 0.89 (0.79-1.00) 0.051
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